ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD137 Agonistic Monoclonal Antibody CTX-471

Its studies are mostly in Carcinoma, Neuroendocrine · Neoplasm Metastasis, led by Compass Therapeutics.

Furthest: phase 2, since Jun 17, 20262 company-led studies, 1 open or runningNext primary completion: Sep 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Compass Therapeutics21 open or runningphase 2since Jun 17, 2026Mar 13, 2019Sep 2028phase 2 · NCT07684170

Also a collaborator on its studies: IQVIA Pty.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 13, 2019First study: phase 1 study in Neoplasm MetastasisFirst studyNCT03881488 · 100 enrolled · United States
  2. Jun 17, 2026Phase 2 study in Neuroendocrine TumorsPhase 2 reachedNCT07684170 · 58 planned · United States

Ahead

  1. Sep 2028Primary completion: phase 2 study in Neuroendocrine TumorsNCT07684170

TargetBeta

TNFRSF9 →read by rule
“A fully human immunoglobulin G4 (IgG4) agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule

Other programs on TNFRSF9

ProgramCompanyFurthest phaseStudies
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
acasunlimabruleGenmabphase 36
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 33
CD137/Nectin-4 Bispecific-targeting Agent BT7480rulebicycletx-limitedphase 22
Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314ruleBioNTechphase 22
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleabl-bio-incphase 22
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceuticalphase 22
Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505ruleRegeneron Pharmaceuticalsphase 21
LM-2417Sino Biopharmaceuticalphase 21
clesitamigHoffmann-La Rochephase 12
Anti-CD137/PD-L1 Bispecific Antibody FS222Sino Biopharmaceuticalphase 11
Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015rulemedigene-agphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07684170Neuroendocrine Tumors · United States2RecruitingSep 202858
NCT03881488Neoplasm Metastasis · United States1TerminatedMay 21, 2025100

How it is read

Names in the registry

  • “CTX-471”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.